Solid Malignancies
4
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
ADC
1100%
+ 3 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
GS
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
Carrick TherapeuticsCT7439 Capsules
Zai LabTisotumab Vedotin
Gilead Scienceszamzetoclax
Clinical Trials (4)
Total enrollment: 194 patients across 4 trials
Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)
30 patients
Phase 2Unknown
A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
Start: Aug 2024Est. completion: May 2026
Phase 1/2Recruiting
To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
Start: Jun 2023Est. completion: Nov 202319 patients
Phase 1Completed
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
Start: Sep 2021Est. completion: Mar 2029145 patients
Phase 1Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 194 patients
4 companies competing in this space